Media Inquiries

Meredith Kaya

Vice President, Investor Relations and Corporate Communications

617.374.5082

mkaya@ironwoodpharma.com

Beth Calitri

Corporate Communications, Media Relations

978.417.2031

bcalitri@ironwoodpharma.com
Sort by Year
October 27, 2009

Marsha Fanucci Joins Ironwood Board of Directors

September 14, 2009

David Ebersman Joins Ironwood Board of Directors

September 14, 2009

Ironwood Appoints Thomas McCourt as Chief Commercial Officer and Senior Vice President of Marketing and Sales

May 31, 2009

Ironwood And Forest Present Additional Positive Phase 2b Study Results For Linaclotide In Patients With Irritable Bowel Syndrome With Constipation

May 12, 2009

Ironwood And Forest To Present Additional Phase 2b Data For Novel Gastrointestinal Agent Linaclotide

May 4, 2009

Ironwood Announces Linaclotide European Licensing Agreement With Almirall

October 21, 2008

Ironwood Presents Positive Phase 2b Study Results for Linaclotide in Patients with Irritable Bowel Syndrome with Constipation

October 7, 2008

Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients with Irritable Bowel Syndrome with Constipation

October 6, 2008

Ironwood and Collaborators Present Preclinical Data Demonstrating that Cyclic GMP Alleviates Intestinal Pain

October 1, 2008

Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3

September 23, 2008

Ironwood and Forest to Present Positive Data from Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference

May 20, 2008

Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results

April 7, 2008

Microbia Announces Name Change to Ironwood Pharmaceuticals

March 31, 2008

Microbia Appoints Halley Gilbert as Vice President, General Counsel

March 4, 2008

Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2B Studies

Copyright © 2020, Ironwood Pharmaceuticals, Inc. All Rights Reserved

LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.